Akorn Gains Approval for OTC Generic Flonase
FDA has approved an Akorn ANDA for an over-the-counter version of GlaxoSmithKline’s Flonase (fluticasone propionate) nasal spray USP, 50 mcg per spray, indicated for the temporary relief of hay fever and other upper respiratory allergies in adult and pediatric patients four years of age and older. Akorn says it is exploring private label possibilities, and it has a supply agreement in place for the product to be marketed as Fluticare through Innovus Pharmaceuticals.